Suzanne Elvidge

Biography for Suzanne Elvidge

Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at selvidge@fiercemarkets.com. Follow @suzannewriter on Twitter.

Articles by Suzanne Elvidge

IIL developing firsts for vaccines in India

Chikungunya and Japanese encephalitis virus (JEV) are both mosquito-borne viruses, and Indian Immunologicals Limited is working on what could be the world's first chikungunya vaccine, as well as...

UPDATED: Research paving way to salmonella vaccine

Salmonella is a bacteria found in both humans and animals. It causes food poisoning, and infections can be particularly dangerous in children and the elderly. Antibiotics are becoming ineffective

Gynecological cancer vaccine enters clinical trials

While the incidence of ovarian cancer is around a fifth of that of breast cancer, the number of deaths from the disease is about half of the more common breast cancer. Despite surgery and...

Therapeutic HIV vaccine in clinical trials

Most HIV vaccines in development are designed to protect people against infection. However, a vaccine in development in Antwerp is focusing on harnessing individuals' own immune systems to target and

Sanofi's Shantha Biotechnics hopes to relaunch vaccine

Sanofi ($SNY) subsidiary Shantha Biotechnics has told The Hindu Business Line it plans to relaunch its pentavalent vaccine, Shan5, next year after a new WHO audit. In August 2010, the World Health

Merck's RotaTeq not linked with bowel problems

In the past, vaccines against rotavirus, an infection causing severe diarrhea, have been linked with serious bowel problems and blockages in infants, but a large-scale study of over three-quarters of

Researchers target vaccines for the First Nation

Some ethnic groups are more vulnerable to particular diseases than others, and if these are smaller groups, they may be overlooked in drug and vaccine development. Researchers from the Northern

Hints of a heroin vaccine from Mexico

A vaccine against drug addiction is a bit of holy grail in the war on drugs--one shot, and addicts don't get a kick from the drug anymore. Perhaps even one shot, and teens will never get hooked. But

Bacterial cancer vaccines show glimpses of activity

Therapeutic vaccines could prove to be a good way to tackle cancer. A few shots and--it is hoped--only a few side effects, rather than long treatments with traditional chemotherapy drugs that make...

Novartis' Bexsero successfully protects vast majority of infants

A vaccine against meningococcal B disease, a devastating bacterial infection that is hard to diagnose and can kill in 24 hours, has come a step closer with infant Phase IIb data for Novartis' ($NVS)